AnaptysBio, Inc (ANAB) stock
Close on Oct 19, 2026Market cap $1.73BP/E –Yield –
AnaptysBio, Inc grew revenue 13.0% to $191.57M over the twelve months to Sep 30, 2026. Operating income rose 52.9% to $298.13M, moving the operating margin from 115.1% to 155.6%. Free cash flow was $19.61M. At the latest close the market valued the company at $1.73B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.73B
- P/E ratio
- –
- Price to sales
- 9.01
- Price to book
- 82.95
- Dividend yield
- –
- Free cash flow yield
- 1.14%
Fundamentals
- Revenue
- $191.57M
- Net income
- $184.49M
- EPS, diluted
- -$0.44
- Free cash flow
- $19.61M
- Book value per share
- $0.59
- Diluted shares
- 35M
Trading
- Previous close
- $46.61
- Open
- $47.33
- Day's range
- $47.33 – $49.88
- Volume
- 468,355
- Average volume (20 days)
- 574,248
- Index membership
- Russell 2000, Russell 3000
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANAB | S&P 500 | Difference | ANAB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.8% | +0.6% | −11.4 pts | ||
| 3 months | -15.1% | +3.4% | −18.5 pts | ||
| Year to date | +52.4% | +13.3% | +39.1 pts | ||
| 1 year | +113.3% | +16.6% | +96.7 pts | ||
| 3 years | +314.5% | +86.4% | +228.1 pts | +60.6% | +23.1% |
| 5 years | +169.2% | +81.9% | +87.3 pts | +21.9% | +12.7% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AnaptysBio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Update
- Update
- Results
About AnaptysBio
Pharmaceutical Preparations
AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the research, development, and commercialization of antibody product candidates. The company develops therapeutic antibodies targeting various diseases across its research, development, and collaborative program segments. Its pipeline and partnered assets include rosnilimab, imsidolimab, ANB032, ANB033, ANB101, and dostarlimab, an anti-PD-1 therapy marketed under the name Jemperli. The company partners with and licenses its therapeutic assets to global biopharmaceutical corporations, including GlaxoSmithKline, Vanda Pharmaceuticals, and Centessa Pharmaceuticals.
Company profile, executives and historyAnaptysBio stock: common questions
What is AnaptysBio's stock price?
ANAB closed at $49.24 on Oct 19, 2026, up 5.64% on the day.
What is AnaptysBio's market cap?
AnaptysBio was worth $1.73B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ANAB's P/E ratio?
AnaptysBio lost money over fiscal 2025 (diluted EPS -$0.44), so it has no meaningful P/E ratio.
How much revenue does AnaptysBio make?
AnaptysBio reported revenue of $191.57M for the twelve months to Sep 30, 2026, up 13.0% from a year earlier.
Does AnaptysBio pay a dividend?
No. AnaptysBio has not paid a cash dividend over the last twelve months.
How has ANAB stock performed over the past year?
Including dividends, ANAB returned +113.3% over the past year, against +16.6% for the S&P 500.
Who are AnaptysBio's competitors?
Companies most similar to AnaptysBio by business, industry and size include ZYME, XNCR, IDYA, LGND, SNDX.
See a number that looks wrong?